Stoke Therapeutics (STOK) is drawing investor attention after recent share price moves, with the stock roughly flat over the past day but down over the past week, month and past 3 months.

Zooming out, the recent soft 7 day and 90 day share price returns sit alongside a 1 year total shareholder return of about 157% and a 3 year total shareholder return approaching 2x. This suggests strong long term gains despite recent cooling momentum.

If you are comparing Stoke Therapeutics with other opportunities in healthcare, this could be a useful moment to scan a curated list of 39 healthcare AI stocks.

So, with Stoke Therapeutics having delivered very strong multi-year shareholder returns, while recent momentum has cooled and the stock trades well below some intrinsic and analyst estimates, is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 13.1% Undervalued

On the numbers, Stoke Therapeutics' widely followed fair value of $35 sits above the last close at $30.40, framing the stock as underpriced in that narrative.

This narrative explores a more pessimistic perspective on Stoke Therapeutics compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.

The bearish analysts are assuming Stoke Therapeutics' revenue will decrease by 50.0% annually over the next 3 years.

Curious how a cautious view can still support a higher fair value for Stoke Therapeutics? Revenue swings, margin shifts and a punchy future earnings multiple sit at the core of this narrative, and the full breakdown shows exactly how those ingredients add up.

Result: Fair Value of $35 (UNDERVALUED)

However, Stoke Therapeutics still faces meaningful risks, including potential setbacks in the EMPEROR Phase III trial and tougher payer decisions that could affect pricing, uptake, and margins.

Next Steps

With Stoke Therapeutics presenting both strong past shareholder returns and clear risks, now is a good time to review the numbers yourself, weigh the trade off between concerns and potential rewards, and see the full picture in the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Stoke Therapeutics?

If Stoke Therapeutics has sharpened your focus on quality opportunities, do not stop here. Broaden your watchlist with other ideas sourced from the Simply Wall St Screener.

• Target potential mispricings by scanning for companies that look compelling on quality and value using the 43 high quality undervalued stocks.
• Prioritise resilience by reviewing stocks that show robust financial positions through the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for underfollowed opportunities that still meet strict fundamentals using the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.